Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701763 | 0.86 | HDAC3 (0.61) | HDAC8HDAC6HTTLMNAALDH1A1 | |
| SCHEMBL14947453 | 0.83 | HDAC2 (0.73) | HDAC2HDAC8HDAC6HTTLMNA | |
| SCHEMBL4070835 | 0.83 | HDAC2 (0.77) | HDAC2HDAC8HDAC6HTTLMNA | |
| SCHEMBL5032437 | 0.80 | HDAC2 (0.73) | HDAC2HDAC8HDAC6HTTLMNA | |
| SCHEMBL13701740 | 0.80 | LMNA (0.58) | HDAC2HDAC8HDAC6HTTLMNA | |
| SCHEMBL13701748 | 0.79 | HDAC2 (0.68) | HDAC2HDAC8HDAC6HTTLMNA | |
| SCHEMBL5681701 | 0.78 | HTT (0.87) | HDAC2HDAC8HDAC6HTTLMNA | |
| SCHEMBL13186461 | 0.77 | HDAC8 (0.72) | HDAC2HDAC8HDAC6HTTLMNA | |
| SCHEMBL2282705 | 0.77 | MAOA (0.48) | HTTLMNAALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL13701703 | 0.77 | SMN1; SMN2 (0.58) | HTTLMNAALDH1A1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | HDAC2 2043/4885HDAC8 1490/4885HDAC6 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.